Compounds > captopril
Page last updated: 2024-08-23

captopril and Atherogenesis

captopril has been researched along with Atherogenesis in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Hu, Z; Li, M; Li, S; Shao, J; Wang, Z; Xia, H; Yu, L1
Fiedler, R; Girndt, M; Seibert, E; Trojanowicz, B; Ulrich, C1
Chen, L; Chen, P; Hu, LQ; Li, HQ; Li, TT; Rong, R; Tang, J; Yin, CS; Zhang, Q1
Buller, C; Duncan, J; Kiaii, M; Levin, A; Rose, C; Schachter, ME; Taylor, P; Zalunardo, N1
Darrow, AL; Leo, GC1
Abd Alla, J; Arman-Kalcek, G; Elzahwy, SS; Langer, A; Quitterer, U; Streichert, T1
Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H1
Babar, S; Ducobu, J; Legssyer, I; Moguilevsky, N; Moreau, P; Nève, J; Van Antwerpen, P; Vanhaeverbeek, M; Zouaoui Boudjeltia, K1

Other Studies

8 other study(ies) available for captopril and Atherogenesis

ArticleYear
Captopril Attenuates the Upregulated Connexin 43 Expression in Artery Calcification.
    Archives of medical research, 2020, Volume: 51, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Atherosclerosis; Calcium-Binding Proteins; Captopril; Connexin 43; Down-Regulation; Extracellular Matrix Proteins; Extracellular Signal-Regulated MAP Kinases; Male; Matrix Gla Protein; Microfilament Proteins; Muscle Proteins; RANK Ligand; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Up-Regulation; Vascular Calcification; Vascular Stiffness; Vitamin K 1; Warfarin

2020
Uremic conditions drive human monocytes to pro-atherogenic differentiation via an angiotensin-dependent mechanism.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cell Adhesion; Cell Line; Cell Movement; Cell Proliferation; Humans; Lipopolysaccharides; Losartan; Monocytes; Peptidyl-Dipeptidase A; Uremia

2014
Captopril inhibits maturation of dendritic cells and maintains their tolerogenic property in atherosclerotic rats.
    International immunopharmacology, 2015, Volume: 28, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Aorta; Atherosclerosis; Captopril; Cholesterol; Cytokines; Dendritic Cells; Diet, Atherogenic; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Lipids; Male; Rats, Sprague-Dawley; Simvastatin; T-Lymphocytes, Regulatory

2015
Incidental atherosclerotic renal artery stenosis in patients undergoing elective coronary angiography: are these lesions significant?
    American journal of nephrology, 2009, Volume: 29, Issue:5

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atherosclerosis; Captopril; Cohort Studies; Coronary Angiography; Female; Humans; Incidental Findings; Male; Mass Screening; Renal Artery Obstruction; Retrospective Studies

2009
NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice.
    Magnetic resonance in chemistry : MRC, 2009, Volume: 47 Suppl 1

    Topics: Animals; Antihypertensive Agents; Apolipoproteins E; Atherosclerosis; Biomarkers; Captopril; Disease Models, Animal; Magnetic Resonance Spectroscopy; Metabolomics; Mice; Mice, Knockout; Reference Standards

2009
Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.
    The Journal of biological chemistry, 2010, Jul-23, Volume: 285, Issue:30

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Captopril; Chemokines, CC; Cholesterol; Coronary Artery Disease; Down-Regulation; Female; Hematopoietic Stem Cells; Humans; Macrophages; Male; Mice; Middle Aged; Monocytes; Oligonucleotide Array Sequence Analysis; Peptidyl-Dipeptidase A; Protein Transport; Receptor, Angiotensin, Type 1; Receptors, CCR; Substrate Specificity; T-Lymphocytes

2010
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Journal of the American College of Cardiology, 2006, Feb-21, Volume: 47, Issue:4

    Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan

2006
Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.
    European journal of pharmacology, 2006, May-10, Volume: 537, Issue:1-3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Apolipoprotein B-100; Apolipoproteins B; Atherosclerosis; Captopril; Enalapril; Fosinopril; Humans; Hydrogen Peroxide; Hypochlorous Acid; Lipoproteins, LDL; Lisinopril; Oxidation-Reduction; Peroxidase; Ramipril; Recombinant Proteins

2006